Anastrozole Tablet
Product Images NDC 71335-1879

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Anastrozole (NDC 71335-1879). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Anastrozole 01)

Chemical structure diagram of anastrozole, showing the arrangement of atoms and rings characteristic of this active ingredient.*

FDA Label Image

Figure 1 (Anastrozole 02)

A line graph comparing disease-free survival in months between two randomized treatments, anastrozole and tamoxifen. The vertical axis shows the proportion of patients alive and disease-free, and the horizontal axis represents months. The graph includes a table presenting the number of patients at risk over time for each treatment group.*

FDA Label Image

Figure 2 (Anastrozole 03)

A Kaplan-Meier survival curve displaying disease-free survival over approximately 90 months. The y-axis shows the proportion of patients alive and disease-free, while the x-axis represents time in months. Two lines compare outcomes between randomized treatments of anastrozole (dashed line) and tamoxifen (solid line). Patient count at risk is listed below the x-axis for both treatment groups at various time points.*

FDA Label Image

Figure 3 (Anastrozole 04)

A Kaplan-Meier survival curve graph comparing proportion event-free over time in months between two randomized treatments: Anastrozole (solid line) and Tamoxifen (dashed line). The X-axis shows time to event in months (0 to 120), and the Y-axis shows the proportion event-free (from 0.50 to 1.00). Below the graph is a table displaying the number of patients at risk for each treatment group at different months.*

FDA Label Image

Figure 4 (Anastrozole 05)

A Kaplan-Meier survival curve graph comparing Anastrozole and Tamoxifen treatments over 120 months. The y-axis shows the proportion event free, and the x-axis shows time to event in months. A table beneath lists the number of patients at risk for each treatment at multiple time points. The vertical axis is truncated to clarify the curves.*

FDA Label Image

Figure 5 (Anastrozole 06)

A Kaplan-Meier curve chart depicting the proportion of patients not progressing over time in months for two randomized treatments: Anastrozole (solid line) and Tamoxifen (dashed line). The x-axis represents time to progression in months, ranging from 0 to 42, and the y-axis represents the proportion not progressing, from 0 to 1. The chart includes the number of patients at risk for each treatment at various time points.*

FDA Label Image

Figure 6 (Anastrozole 07)

A Kaplan-Meier survival curve comparing the time to progression in months for two randomized treatments: Anastrozole and Tamoxifen. The vertical axis shows the proportion of patients not progressing, while the horizontal axis represents time in months up to 42 months. A risk table is displayed below, showing patient counts at various time points for each treatment group.*

FDA Label Image

Label (Lbl713351879)

Anastrozole 1 mg tablet packaging label from Bryant Ranch Prepack in Burbank, CA. The label states the product is comparable to Arimidex 1 mg tablet by Natco Pharma Limited. It includes storage instructions to keep in a light-resistant container at 20°-25°C (68°-77°F) and mentions it is for prescription use only. The package contains 30 tablets. The NDC on the label is 71335-1879-1.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.